Covered recipient · General Payments record
GNANAGURDASAN PRAKASAM
Allopathic & Osteopathic Physicians Pediatrics Pediatric Endocrinology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$97,245.98
229 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $76,922.02 | 44 |
| Travel and Lodging | $10,943.38 | 39 |
| Consulting Fee | $6,162.50 | 4 |
| Food and Beverage | $3,158.68 | 141 |
| Gift | $59.40 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk Inc | $32,282.79 | 45 |
| Lilly USA, LLC | $16,290.15 | 18 |
| Kyowa Kirin, Inc. | $10,809.51 | 20 |
| ABBVIE INC. | $10,404.95 | 61 |
| SANOFI-AVENTIS U.S. LLC | $9,963.32 | 15 |
| Alexion Pharmaceuticals, Inc. | $8,707.55 | 11 |
| Ultragenyx Pharmaceutical Inc. | $6,852.50 | 11 |
| MannKind Corporation | $1,225.43 | 16 |
| Abbott Laboratories | $288.25 | 13 |
| Ascendis Pharma Inc | $78.64 | 3 |
| Tolmar, Inc. | $73.13 | 3 |
| PFIZER INC. | $71.23 | 3 |
| Azurity Pharmaceuticals, Inc. | $41.14 | 2 |
| BioMarin Pharmaceutical Inc. | $38.87 | 2 |
| Xeris Pharmaceuticals, Inc. | $37.16 | 2 |
| Tandem Diabetes Care, Inc. | $25.73 | 1 |
| Dexcom, Inc. | $21.93 | 1 |
| Embecta Corp. | $20.85 | 1 |
| Regeneron Healthcare Solutions, Inc. | $12.85 | 1 |
Page 3 of 5; records 101–150 of 229 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
GNANAGURDASAN PRAKASAM
NPI 1871586065 · CMS profile ID 176290
Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Endocrinology
SACRAMENTO, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 5; records 101–150 of 229 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1871586065?year=2023&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- GNANAGURDASAN PRAKASAM, NPI 1871586065, CMS profile ID 176290. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 229 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1871586065?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). GNANAGURDASAN PRAKASAM, NPI 1871586065, CMS profile ID 176290. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 229 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1871586065?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- GNANAGURDASAN PRAKASAM, NPI 1871586065, CMS profile ID 176290, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 229 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1871586065?year=2023&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
229 matching records · $97,245.98 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 229.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc | $131.20 | 08/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000378091 | CMS |
| Novo Nordisk Inc | $206.82 | 08/02/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000378119 | CMS |
| Novo Nordisk Inc | $316.51 | 08/02/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000378143 | CMS |
| Novo Nordisk Inc | $878.77 | 08/02/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000378191 | CMS |
| Novo Nordisk Inc | $4,781.25 | 08/02/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000397569 | CMS |
| Kyowa Kirin, Inc. | $97.44 | 07/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026996241 | CMS |
| Kyowa Kirin, Inc. | $340.32 | 07/26/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026996269 | CMS |
| Kyowa Kirin, Inc. | $651.91 | 07/26/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026996273 | CMS |
| MannKind Corporation | $18.34 | 07/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056293669 | CMS |
| ABBVIE INC. | $17.23 | 07/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998160285 | CMS |
| ABBVIE INC. | $2.50 | 07/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998160287 | CMS |
| ABBVIE INC. | $2.27 | 07/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998160289 | CMS |
| Lilly USA, LLC | $22.17 | 07/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031654117 | CMS |
| ABBVIE INC. | $12.01 | 07/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998160277 | CMS |
| ABBVIE INC. | $0.81 | 07/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998160279 | CMS |
| ABBVIE INC. | $0.73 | 07/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998160281 | CMS |
| ABBVIE INC. | $3.40 | 07/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998160283 | CMS |
| Lilly USA, LLC | $1,100.00 | 07/17/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031501837 | CMS |
| Regeneron Healthcare Solutions, Inc. | $12.85 | 07/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999374003 | CMS |
| SANOFI-AVENTIS U.S. LLC | $28.54 | 07/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050452621 | CMS |
| Abbott Laboratories | $22.02 | 07/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1018951215 | CMS |
| Alexion Pharmaceuticals, Inc. | $1,350.00 | 06/29/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017081369 | CMS |
| Lilly USA, LLC | $1,100.00 | 06/28/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031474189 | CMS |
| MannKind Corporation | $20.44 | 06/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056293665 | CMS |
| Kyowa Kirin, Inc. | $77.45 | 06/27/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026996201 | CMS |
| Kyowa Kirin, Inc. | $57.78 | 06/27/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026996205 | CMS |
| Kyowa Kirin, Inc. | $6.51 | 06/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026996209 | CMS |
| Kyowa Kirin, Inc. | $35.73 | 06/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026996213 | CMS |
| Kyowa Kirin, Inc. | $35.00 | 06/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026996217 | CMS |
| Kyowa Kirin, Inc. | $5,940.00 | 06/23/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026996221 | CMS |
| ABBVIE INC. | $3.05 | 06/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998160271 | CMS |
| ABBVIE INC. | $3.57 | 06/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998160273 | CMS |
| ABBVIE INC. | $3.01 | 06/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998160275 | CMS |
| Abbott Laboratories | $22.14 | 06/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1018951155 | CMS |
| Kyowa Kirin, Inc. | $21.26 | 06/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026996233 | CMS |
| ABBVIE INC. | $3.30 | 06/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998160269 | CMS |
| Novo Nordisk Inc | $21.57 | 06/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000378031 | CMS |
| Tandem Diabetes Care, Inc. | $25.73 | 06/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1060276907 | CMS |
| Novo Nordisk Inc | $6.62 | 06/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000377989 | CMS |
| Ascendis Pharma Inc | $25.61 | 06/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014548573 | CMS |
| Lilly USA, LLC | $1,100.00 | 06/13/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031501835 | CMS |
| Lilly USA, LLC | $550.00 | 06/09/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031482439 | CMS |
| Alexion Pharmaceuticals, Inc. | $218.88 | 06/08/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016989571 | CMS |
| Alexion Pharmaceuticals, Inc. | $32.00 | 06/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017071947 | CMS |
| Lilly USA, LLC | $1,100.00 | 06/08/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031474185 | CMS |
| Lilly USA, LLC | $1,100.00 | 06/08/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031686095 | CMS |
| ABBVIE INC. | $13.74 | 06/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998160265 | CMS |
| ABBVIE INC. | $2.76 | 06/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998160267 | CMS |
| Alexion Pharmaceuticals, Inc. | $73.18 | 06/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016993261 | CMS |
| Alexion Pharmaceuticals, Inc. | $3,600.00 | 06/06/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017087175 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $441,048.05 | 62 |
| PY2024 | Principal investigator | $698,877.58 | 643 |
| PY2023 | Principal investigator | $468,256.83 | 448 |
| PY2022 | Recipient | $3,200.00 | 1 |
| PY2022 | Principal investigator | $292,265.21 | 229 |
| PY2021 | Recipient | $1,635.09 | 4 |
| PY2021 | Principal investigator | $238,681.85 | 69 |
| PY2020 | Recipient | $7,054.41 | 5 |
| PY2020 | Principal investigator | $419,100.59 | 92 |
| PY2019 | Recipient | $16,285.90 | 3 |
| PY2019 | Principal investigator | $421,262.47 | 117 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
62 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $449.60 | 12/31/2025 | Covered Recipient Teaching Hospital Sutter Medical Center - Sacramento | A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control | No dispute reported | 06/30/2026 | 1232917995 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $3,183.30 | 12/22/2025 | Covered Recipient Teaching Hospital Sutter Medical Center - Sacramento | BMN 111-210 | No dispute reported | 06/30/2026 | 1248578840 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $8,017.65 | 12/22/2025 | Covered Recipient Teaching Hospital Sutter Medical Center - Sacramento | BMN 111-210 | No dispute reported | 06/30/2026 | 1248578842 |
| Principal investigator 1 | Novo Nordisk AS | $600.00 | 12/22/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4469 | No dispute reported | 06/30/2026 | 1213743307 |
| Principal investigator 1 | Novo Nordisk AS | $4,138.92 | 12/22/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4469 | No dispute reported | 06/30/2026 | 1213772480 |
| Principal investigator 1 | Novo Nordisk AS | $75.00 | 12/22/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4469 | No dispute reported | 06/30/2026 | 1213790867 |
| Principal investigator 1 | Novo Nordisk AS | $200.00 | 12/22/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4469 | No dispute reported | 06/30/2026 | 1213808834 |
| Principal investigator 1 | Novo Nordisk AS | $890.00 | 12/22/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4469 | No dispute reported | 06/30/2026 | 1213822462 |
| Principal investigator 1 | Novo Nordisk AS | $25.00 | 12/22/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4469 | No dispute reported | 06/30/2026 | 1213825212 |
| Principal investigator 1 | Novo Nordisk AS | $2,160.00 | 11/20/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4469 | No dispute reported | 06/30/2026 | 1213819467 |
| Principal investigator 1 | Novo Nordisk AS | $800.00 | 10/29/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4469 | No dispute reported | 06/30/2026 | 1213709674 |
| Principal investigator 1 | Novo Nordisk AS | $100.00 | 10/29/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4469 | No dispute reported | 06/30/2026 | 1213775783 |
| Principal investigator 1 | Novo Nordisk AS | $1,620.00 | 10/29/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4469 | No dispute reported | 06/30/2026 | 1213777182 |
| Principal investigator 1 | Novo Nordisk AS | $890.00 | 10/29/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4469 | No dispute reported | 06/30/2026 | 1213828173 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $2,046.80 | 10/09/2025 | Covered Recipient Teaching Hospital Sutter Medical Center - Sacramento | SkybriGHt | No dispute reported | 06/30/2026 | 1233997163 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $1,914.20 | 10/09/2025 | Covered Recipient Teaching Hospital Sutter Medical Center - Sacramento | SkyPASS | No dispute reported | 06/30/2026 | 1233997167 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $3,999.00 | 10/01/2025 | Covered Recipient Teaching Hospital Sutter Davis Hospital | A Phase 2, Randomized, Controlled, Multicenter Study of Vosoritide in Children With Idiopathic Short Stature | No dispute reported | 06/30/2026 | 1248578826 |
| Principal investigator 1 | Eli Lilly and Company | $1,743.00 | 09/29/2025 | Covered Recipient Teaching Hospital SUTTER MEDICAL CENTER - SACRAMENTO | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY WITH AN OPEN-LABEL EXTENSION ASSESSING THE EFFICACY, SAFETY, AND PHARMACOKINETICS PHARMACODYNAMICS OF TIRZEPATIDE IN PEDIATRIC AND ADOLESCENT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED WITH METFORMIN, OR BASAL INSULIN, OR BOTH | No dispute reported | 06/30/2026 | 1187874751 |
| Principal investigator 1 | Eli Lilly and Company | $95,164.00 | 09/23/2025 | Covered Recipient Teaching Hospital SUTTER MEDICAL CENTER - SACRAMENTO | EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR THE TREATMENT OF OBESITY AND WEIGHT-RELATED COMORBIDITIES IN ADOLESCENTS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED TRIAL (SURMOUNT-ADOLESCENTS-2) | No dispute reported | 06/30/2026 | 1187875089 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $1,500.00 | 09/19/2025 | Covered Recipient Teaching Hospital Sutter Medical Center - Sacramento | BMN 111-210 | No dispute reported | 06/30/2026 | 1248578838 |
| Principal investigator 1 | Novo Nordisk AS | $400.00 | 09/19/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4469 | No dispute reported | 06/30/2026 | 1213719863 |
| Principal investigator 1 | Novo Nordisk AS | $25.00 | 09/19/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4469 | No dispute reported | 06/30/2026 | 1213835382 |
| Principal investigator 1 | Dexcom, Inc. | $3,862.00 | 09/03/2025 | Non-covered Recipient Entity Center of Excellence in Diabetes and Endocrinology | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | No dispute reported | 06/30/2026 | 1250961568 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $3,070.20 | 08/26/2025 | Covered Recipient Teaching Hospital Sutter Medical Center - Sacramento | SkybriGHt | No dispute reported | 06/30/2026 | 1233996701 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $2,871.30 | 08/26/2025 | Covered Recipient Teaching Hospital Sutter Medical Center - Sacramento | SkyPASS | No dispute reported | 06/30/2026 | 1233996703 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $13,734.00 | 08/25/2025 | Covered Recipient Teaching Hospital Sutter Medical Center - Sacramento | BMN 111-903 | No dispute reported | 06/30/2026 | 1248578834 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $4,550.85 | 08/25/2025 | Covered Recipient Teaching Hospital Sutter Medical Center - Sacramento | BMN 111-210 | No dispute reported | 06/30/2026 | 1248578836 |
| Principal investigator 1 | Novo Nordisk AS | $1,967.04 | 08/22/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4467 | No dispute reported | 06/30/2026 | 1213702318 |
| Principal investigator 1 | Novo Nordisk AS | $810.00 | 08/22/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4469 | No dispute reported | 06/30/2026 | 1213773411 |
| Principal investigator 1 | Novo Nordisk AS | $2,500.00 | 08/04/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4469 | No dispute reported | 06/30/2026 | 1213842524 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $1,023.40 | 07/31/2025 | Covered Recipient Teaching Hospital Sutter Medical Center - Sacramento | SkybriGHt | No dispute reported | 06/30/2026 | 1233996613 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $957.10 | 07/31/2025 | Covered Recipient Teaching Hospital Sutter Medical Center - Sacramento | SkyPASS | No dispute reported | 06/30/2026 | 1233996617 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $3,238.65 | 07/25/2025 | Covered Recipient Teaching Hospital Sutter Medical Center - Sacramento | BMN 111-210 | No dispute reported | 06/30/2026 | 1248578832 |
| Principal investigator 1 | Dexcom, Inc. | $13,476.00 | 07/22/2025 | Non-covered Recipient Entity Center of Excellence in Diabetes and Endocrinology | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | No dispute reported | 06/30/2026 | 1250961564 |
| Principal investigator 1 | Novo Nordisk AS | $2,160.00 | 07/16/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4469 | No dispute reported | 06/30/2026 | 1213764365 |
| Principal investigator 1 | Dexcom, Inc. | $7,118.00 | 07/08/2025 | Non-covered Recipient Entity Center of Excellence in Diabetes and Endocrinology | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | No dispute reported | 06/30/2026 | 1250961566 |
| Principal investigator 1 | Novo Nordisk AS | $2,160.00 | 06/30/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4469 | No dispute reported | 06/30/2026 | 1213794822 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $10,146.60 | 06/25/2025 | Covered Recipient Teaching Hospital Sutter Medical Center - Sacramento | BMN 111-210 | No dispute reported | 06/30/2026 | 1248578830 |
| Principal investigator 1 | Dexcom, Inc. | $6,779.00 | 06/10/2025 | Non-covered Recipient Entity Center of Excellence in Diabetes and Endocrinology | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | No dispute reported | 06/30/2026 | 1250961574 |
| Principal investigator 1 | Novo Nordisk AS | $1,800.00 | 05/21/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4469 | No dispute reported | 06/30/2026 | 1213703182 |
| Principal investigator 1 | Novo Nordisk AS | $5,902.87 | 05/21/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4263 | No dispute reported | 06/30/2026 | 1213723030 |
| Principal investigator 1 | Dexcom, Inc. | $38,012.00 | 05/13/2025 | Non-covered Recipient Entity Center of Excellence in Diabetes and Endocrinology | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | No dispute reported | 06/30/2026 | 1250961572 |
| Principal investigator 1 | BioMarin Pharmaceutical Inc. | $5,073.30 | 05/02/2025 | Covered Recipient Teaching Hospital Sutter Medical Center - Sacramento | BMN 111-210 | No dispute reported | 06/30/2026 | 1248578828 |
| Principal investigator 1 | Dexcom, Inc. | $9,126.00 | 04/28/2025 | Non-covered Recipient Entity Center of Excellence in Diabetes and Endocrinology | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | No dispute reported | 06/30/2026 | 1250961570 |
| Principal investigator 1 | Dexcom, Inc. | $18,490.00 | 04/28/2025 | Non-covered Recipient Entity Center of Excellence in Diabetes and Endocrinology | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | No dispute reported | 06/30/2026 | 1250961576 |
| Principal investigator 1 | Dexcom, Inc. | $32,287.00 | 04/28/2025 | Non-covered Recipient Entity Center of Excellence in Diabetes and Endocrinology | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | No dispute reported | 06/30/2026 | 1250961578 |
| Principal investigator 1 | Novo Nordisk AS | $150.00 | 04/21/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4469 | No dispute reported | 06/30/2026 | 1213718096 |
| Principal investigator 1 | Novo Nordisk AS | $2,315.00 | 04/21/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4469 | No dispute reported | 06/30/2026 | 1213727836 |
| Principal investigator 1 | Novo Nordisk AS | $810.00 | 04/21/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4469 | No dispute reported | 06/30/2026 | 1213809309 |
| Principal investigator 1 | PFIZER INC. | $1,500.00 | 04/02/2025 | Covered Recipient Teaching Hospital Sutter Davis Hospital | PFIZER REGISTRY OF OUTCOMES IN GROWTH HORMONE RESEARCH PROGRES A MULTI COUNTRY NONINTERVENTIONAL PROSPECTIVE COHORT STUDY AMONG PATIENTS WITH HUMAN GROWTH HORMONE HGH TREATMENTS UNDER ROUTINE CLINICAL CARE | No dispute reported | 06/30/2026 | 1228851336 |
| Principal investigator 1 | Novo Nordisk AS | $810.00 | 03/28/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4469 | No dispute reported | 06/30/2026 | 1213776664 |
| Principal investigator 1 | Dexcom, Inc. | $303.00 | 03/11/2025 | Non-covered Recipient Entity Center of Excellence in Diabetes and Endocrinology | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | No dispute reported | 06/30/2026 | 1250961550 |
| Principal investigator 1 | Dexcom, Inc. | $15,556.75 | 03/11/2025 | Non-covered Recipient Entity Center of Excellence in Diabetes and Endocrinology | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | No dispute reported | 06/30/2026 | 1250961558 |
| Principal investigator 1 | Dexcom, Inc. | $6,183.75 | 03/11/2025 | Non-covered Recipient Entity Center of Excellence in Diabetes and Endocrinology | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | No dispute reported | 06/30/2026 | 1250961562 |
| Principal investigator 1 | Novo Nordisk AS | $2,580.00 | 02/21/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4469 | No dispute reported | 06/30/2026 | 1213740792 |
| Principal investigator 1 | Novo Nordisk AS | $75.00 | 02/21/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4469 | No dispute reported | 06/30/2026 | 1213773637 |
| Principal investigator 1 | Novo Nordisk AS | $2,610.00 | 02/21/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES AND ENDOCRINOLOGY | NN8640-4469 | No dispute reported | 06/30/2026 | 1213800863 |
| Principal investigator 1 | Eli Lilly and Company | $2,654.52 | 01/31/2025 | Non-covered Recipient Entity CENTER OF EXCELLENCE IN DIABETES | EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR THE TREATMENT OF OBESITY AND WEIGHT-RELATED COMORBIDITIES IN ADOLESCENTS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED TRIAL (SURMOUNT-ADOLESCENTS-2) | No dispute reported | 06/30/2026 | 1187879293 |
| Principal investigator 1 | Dexcom, Inc. | $15,490.00 | 01/28/2025 | Non-covered Recipient Entity Center of Excellence in Diabetes and Endocrinology | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | No dispute reported | 06/30/2026 | 1250961552 |
| Principal investigator 1 | Dexcom, Inc. | $6,476.00 | 01/28/2025 | Non-covered Recipient Entity Center of Excellence in Diabetes and Endocrinology | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | No dispute reported | 06/30/2026 | 1250961554 |
| Principal investigator 1 | Dexcom, Inc. | $43,958.00 | 01/28/2025 | Non-covered Recipient Entity Center of Excellence in Diabetes and Endocrinology | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | No dispute reported | 06/30/2026 | 1250961556 |
| Principal investigator 1 | Dexcom, Inc. | $18,519.25 | 01/28/2025 | Non-covered Recipient Entity Center of Excellence in Diabetes and Endocrinology | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | No dispute reported | 06/30/2026 | 1250961560 |